×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Clinical: CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
clinical
3,284 words
KG: CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
Contents
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (26)
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
APOE Isoform Conversion Therapy
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.71
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.67
RNA Granule Nucleation Site Modulation
Score: 0.66
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Vagal Afferent Microbial Signal Modulation
Score: 0.62
Vocal Cord Neuroplasticity Stimulation
Score: 0.52
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
Multi-Modal Stress Response Harmonization
Score: 0.76
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72
Stress Granule Phase Separation Modulators
Score: 0.72
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.68
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67
Nucleolar Stress Response Normalization
Score: 0.65
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.54
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Show 21 more
Related Analyses (11)
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Show 6 more
Related Experiments (4)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
See Also (15)
CD38 Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
FLT3/FLT3L Cytokine Therapy for Neurodegeneration
therapy · Pages share 7 hypotheses
Transdiagnostic Proteomic Changes in Neurodegeneration
gene · Pages share 7 hypotheses
BDNF Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
CRISPR/Cas9 Gene Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Exosome Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 7 hypotheses
Neurodegeneration
disease · Pages share 7 hypotheses
Advanced Cytoskeletal Dynamics Modulator Therapy for Ne
therapeutic · Pages share 7 hypotheses
Antisense Oligonucleotide Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Cerebrolysin Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
cGAS-STING Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
DNA Repair Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Estrogen Replacement Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Hyperbaric Oxygen Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Show 10 more
Knowledge Graph (2 edges)
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
references
APOE
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in AD
references
BDNF
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)